For example: Page 16 shows a 70% five-year survival rate for stage IV carcinoma of the tongue.
FORBES: What Business Can Learn From Cleveland Clinic: How To Report Quality To The Public
Good news for Dendreon and its prostate cancer treatment, Provenge: a rival medicine from AstraZeneca, zibotentan, failed to extend survival in a late stage trial.
One year after diagnosis, survival for women with early-stage breast cancer was close to 100% in all six countries.
But for women with the most advanced breast cancers, one-year survival ranged from 53% in the UK to 67% in Sweden - and there was still a 14% difference between the UK and Sweden in three-year survival for those with late-stage breast cancer.
Gold says the evidence for Provenge is stronger than for other new cancer treatments, with three different late-stage studies showing a combined survival benefit.
The five-year survival rate for those diagnosed at a local stage of disease is 91 percent.
As in late-stage colon cancer, overall median survival was extended by only a few months.
Two-thirds of cases are diagnosed at the local stage, when five-year survival is more than 90 percent.
The late-stage human trial showed a median survival increase of 2.7 months compared with patients who received chemotherapy alone.
Of course those who have an operation, the range is somewhere between 10 or 15 percent to 30 percent survival rate after five years, depending on what stage the cancer is, whether the surgeons could get what are called clean margins, and whether it's metastasized.
The vaccine showed a trend towards higher survival in its initial trial, is now in a final stage trial in 1300 patients with inoperable lung cancer.
Women diagnosed at the earliest stage of ovarian cancer have a five-year survival rate of 92%, but the five-year survival rate in the UK is just 36%, amongst the worst in Europe.
BBC: Northern Ireland women 'slow to recognise ovarian cancer'
He notes that earlier-stage clinical trials of Avastin in breast cancer failed to show any survival trend.
This suggests that lower overall breast cancer survival in the UK is not because women are being diagnosed at a later stage than in other countries, the study says.
In results from a late-stage trial released in August, Vidaza was shown to have increased the survival of patients with a high-risk type of MDS from 15 months to 24 months.
The five-year survival rate is 98% for women whose breast cancer tumors are discovered at their earliest stage.
应用推荐